Stable Expression of Adalimumab in Nicotiana tabacum

Tzvi Zvirin, Lena Magrisso, Amit Yaari, Oded Shoseyov*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Production of monoclonal antibodies and pharmaceutical proteins in transgenic plants has been the focus of many research efforts for close to 30 years. Use of plants as bioreactors reduces large-scale production costs and minimizes risk for human pathogens contamination. Stable nuclear transformation of the plant genome offers a clear advantage in agricultural protein production platforms, limited only by the number of hectares that can be cultivated. We report here, for the first time, successful and stable expression of adalimumab in transgenic Nicotiana tabacum plants. The plant-derived adalimumab proved fully active and was shown to rescue L929 cells from the in vitro lethal effect of rhTNFα just as effectively as commercially available CHO-derived adalimumab (Humira). These results indicate that agricultural biopharming is an efficient alternative to mammalian cell-based expression platforms for the large-scale production of recombinant antibodies.

Original languageAmerican English
Pages (from-to)387-395
Number of pages9
JournalMolecular Biotechnology
Issue number6
StatePublished - 1 Jun 2018

Bibliographical note

Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.


  • Adalimumab
  • Humira
  • Nicotiana tabacum
  • Plant-derived antibody
  • Plant-made pharmaceuticals
  • TNF-α


Dive into the research topics of 'Stable Expression of Adalimumab in Nicotiana tabacum'. Together they form a unique fingerprint.

Cite this